SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the-shelf NK Cell Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Functional Components to Enhance Innate Immunity SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Companys Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy.
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent, U.S. 10,596,169, for methods of treating severe chemotherapy-induced neutropenia (CIN) from Taxane in cancer patients by administering its lead asset Plinabulin, with protection through 2033
The novel coronavirus cant be killed or stopped with the current drugs that we have, the WHO said earlier this week.
HOUSTON, May 11, 2020 /PRNewswire/ --Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.
Microdispensing specialist nScrypt and aerospace company TechShot have successfully completed the first functional 3D bioprinting experiment in space. Using the BioFabrication Facility (BFF) on board the ISS, with the help of the non-profit Geneva Foundation and the Uniformed Services University of the Health Sciences (USU), they 3D bioprinted a human knee meniscus as part of the 4D Bio3 program. The breakthrough experiment is part of a long term plan to one day manufacture advanced soft tissues and whole organs in the microgravity of space.
Stem cell health supplements contain natural components that release stem cells in the body and start the repair mechanism during illnesses. They are excellent for restoring and maintaining good health.
Treatments like stem cell therapy and platelet-rich plasma therapy once were cost-prohibitive for the average pet owner, but now, because of advances in cell processing and methods of stem cell harvest and storage in younger animals at the time of spay/neuter, treatments are much more feasible. Treatments like stem cell therapy and platelet-rich plasma therapy once were cost-prohibitive for the average pet owner, but now, because of advances in cell processing and methods of stem cell harvest and storage in younger animals at the time of spay/neuter, treatments are much more feasible
January 28, 2011, Harri Daniel, Comments Off on Benefits Of Stem Cells Benefits of Stem Cells Stem cells are manufactured in a persons bone marrow and they have a capability of cell renewal unlike other cells. Stem cells have several uses and therefore provide numerous benefits
HOUSTON, May 11, 2020 /PRNewswire/ --Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020. "While we are eager to initiate our planned Phase 2 trial with our novel MultiTAA-specific T cell therapy in patients with acute myeloid leukemia (AML), we anticipate that the initiation of our trial will be delayed by the impacts the COVID-19 pandemic has had on our clinical trial partners and throughout our supply chain. As a result of the uncertainty, we believe it is prudent to withdraw our prior guidance on the timing of this trial until the outlook clarifies," said Peter L.
Recent Comments